Get the Stockscreener App
11.97
10.00%
-1.33
After Hours:
11.97
Embecta Corp stock is traded at $11.97, with a volume of 975.12K.
It is down -10.00% in the last 24 hours and down -5.38% over the past month.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
See More
Previous Close:
$13.30
Open:
$13.3
24h Volume:
975.12K
Relative Volume:
1.72
Market Cap:
$740.05M
Revenue:
$1.12B
Net Income/Loss:
$55.30M
P/E Ratio:
12.60
EPS:
0.95
Net Cash Flow:
$-30.30M
1W Performance:
-5.97%
1M Performance:
-5.38%
6M Performance:
-22.97%
1Y Performance:
-15.47%
1-Day Range:
$11.69
$13.38
1-Week Range:
$11.69
$13.45
52-Week Range:
$10.83
$21.48
Embecta Corp Stock (EMBC) Company Profile
Name
Embecta Corp
Sector
Industry
Phone
(862) 401-0000
Address
1209 ORANGE STREET, WILMINGTON
Compare EMBC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EMBC
Embecta Corp
|
11.97 | 740.05M | 1.12B | 55.30M | -30.30M | 0.95 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Embecta Corp Stock (EMBC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Nov-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-08-22 | Initiated | BTIG Research | Neutral |
| Aug-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-22 | Initiated | BofA Securities | Underperform |
View All
Embecta Corp Stock (EMBC) Latest News
Embecta Corp. (NASDAQ:EMBC) Q2 2025 Earnings Call Transcript - Insider Monkey
Embecta Q2 2025 slides: Revenue decline offset by margin improvement and debt reduction - Investing.com
Embecta Corporation Reports Q2 2025 Financial Results - TipRanks
Embecta earnings beat by $0.17, revenue topped estimates - Investing.com Nigeria
Embecta Corp’s Earnings Call: Progress Amid Challenges - TipRanks
Embecta to undergo further restructuring, lowers guidance amid tariff impact - MassDevice
Embecta reports Q2 adjusted EPS 70c, consensus 59c - TipRanks
Embecta Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Embecta Corp., Q2 2025 Earnings Call, May 09, 2025 - marketscreener.com
Why Is Embecta Stock Falling On Friday? - Yahoo Finance
EMBC Reports Q2 Revenue Slightly Below Expectations, Adjusts Gui - GuruFocus
Embecta Keeps Quarterly Dividend at $0.15 a Share; Payable June 13 to Holders of Record as of May 28 - marketscreener.com
Earnings call transcript: Embecta Q2 2025 beats EPS forecast, stock dips - Investing.com UK
Embecta Corp. (EMBC) Tops Q2 Earnings Estimates - Yahoo Finance
Embecta beats Q2 expectations, maintains full-year EPS outlook By Investing.com - Investing.com Nigeria
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing? - simplywall.st
EMBC Reports Q2 Revenue Slightly Below Expectations, Adjusts Guidance | EMBC Stock News - GuruFocus
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results - Stock Titan
Embecta Corp. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Earnings Flash (EMBC) EMBECTA CORP. Posts Q2 Revenue $259M, vs. FactSet Est of $253.9M - marketscreener.com
Embecta Corp. Updates Earnings Guidance for the Fiscal Year 2025 - marketscreener.com
Is Now An Opportune Moment To Examine Embecta Corp. (NASDAQ:EMBC)? - Yahoo Finance
embecta Announces Quarterly Cash Dividend - Bluefield Daily Telegraph
Embecta Announces Quarterly Cash Dividend - marketscreener.com
EMBECTA Earnings Preview: Recent $EMBC Insider Trading, Hedge Fund Activity, and More - Nasdaq
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference - The Globe and Mail
Embecta To Participate At The J.P. Morgan Global Leveraged Finance Conference - Barchart.com
Embecta Corp. to Host Analyst and Investor Day on May 22, 2025 in New York City - Nasdaq
Embecta to host Analyst and Investor Day on May 22, 2025 - Bluefield Daily Telegraph
Embecta Leaders to Reveal Long-term Growth Strategy and Financial Targets at Exclusive Investor Day - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
embecta to Report Fiscal Second Quarter 2025 Financial Results - The Manila Times
Embecta Corp. to Host Conference Call for Fiscal Q2 2025 Financial Results on May 9, 2025 - Nasdaq
Embecta Corp (EMBC) Stock Price Down 4.37% on Apr 14 - GuruFocus
Mizuho Initiates Coverage of Embecta (EMBC) with Neutral Recommendation - Nasdaq
Mizuho Initiates Embecta at Neutral With $15 Price Target - marketscreener.com
Mizuho sets Embecta stock with Neutral rating, $15 price target By Investing.com - Investing.com Canada
Mizuho sets Embecta stock with Neutral rating, $15 price target - Investing.com
Embecta Corporation: Hold Rating Amid Market Shifts and Strategic Uncertainties - TipRanks
(EMBC) Trading Advice - news.stocktradersdaily.com
Embecta shares study highlighting need for training, standardization in insulin delivery - Drug Delivery Business
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations - GlobeNewswire
Embecta Flat on Publication of Diabetes Education Piece - Baystreet.ca
Major Breakthrough: First Global Insulin Injection Guidelines in 10 Years Released by International Experts - Stock Titan
Embecta announces new publication in Mayo Clinic Proceedings on FITTER - TipRanks
Are Investors Undervaluing Embecta Corp. (NASDAQ:EMBC) By 49%? - Yahoo Finance
embecta recognized as Healthcare Technology Company of the Year - The Healthcare Technology Report.
When the Price of (EMBC) Talks, People Listen - news.stocktradersdaily.com
Bank of New York Mellon Corp Purchases 4,769 Shares of Embecta Corp. (NASDAQ:EMBC) - Defense World
Quantum Computing Just Took Another Giant Leap--What It Means for Investors - The Globe and Mail
Analyzing Embecta (NASDAQ:EMBC) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Embecta Corp Stock (EMBC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):